Patents by Inventor Phillip Febbo

Phillip Febbo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DNA Methylation and Mutational Analysis Methods for Bladder Cancer Surveillance
    Publication number: 20230374604
    Abstract: The present disclosure relates to methods of monitoring bladder cancer patients and analyzing patient samples for presence of methylated DNA and optionally particular gene mutations. In some embodiments, analysis results are correlated with clinical outcome measures such as risk of bladder cancer recurrence.
    Type: Application
    Filed: April 4, 2023
    Publication date: November 23, 2023
    Applicant: Genomic Health, Inc.
    Inventors: Margarita LOPATIN, Athanasios TSIATIS, Christopher N. SILK, David P. MILLER, Michael R. CRAGER, Phillip FEBBO, Dejan KNEZEVIC
  • DNA methylation and mutational analysis methods for bladder cancer surveillance
    Patent number: 11649506
    Abstract: The present disclosure relates to methods of monitoring bladder cancer patients and analyzing patient samples for presence of methylated DNA and optionally particular gene mutations. In some embodiments, analysis results are correlated with clinical outcome measures such as risk of bladder cancer recurrence.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: May 16, 2023
    Assignee: Genomic Health, Inc.
    Inventors: Margarita Lopatin, Athanasios Tsiatis, Christopher N. Silk, David P. Miller, Michael Crager, Phillip Febbo, Dejan Knezevic
  • DNA Methylation and Mutational Analysis Methods for Bladder Cancer Surveillance
    Publication number: 20200165686
    Abstract: The present disclosure relates to methods of monitoring bladder cancer patients and analyzing patient samples for presence of methylated DNA and optionally particular gene mutations. In some embodiments, analysis results are correlated with clinical outcome measures such as risk of bladder cancer recurrence.
    Type: Application
    Filed: May 17, 2018
    Publication date: May 28, 2020
    Applicant: Genomic Health, Inc.
    Inventors: Margarita LOPATIN, Athanasios TSIATIS, Christopher N. SILK, David P. Miller, Michael CRAGER, Phillip FEBBO, Dejan KNEZEVIC
  • Algorithms and Methods for Assessing Late Clinical Endpoints in Prostate Cancer
    Publication number: 20200040400
    Abstract: The present disclosure relates to uses of a multiple gene-expression based Genomic Prostate Score™ (GPS™) algorithm for assessment of various clinical endpoints in prostate cancer patients, such as risks of clinical recurrence (CR), biochemical recurrence (BCR), distant metastasis (Mets), and prostate cancer death (PCD). In some embodiments, GPS result is determined for low and intermediate risk prostate cancer patients in order to assist in determining treatment strategies for those patients.
    Type: Application
    Filed: February 12, 2018
    Publication date: February 6, 2020
    Applicant: Genomic Health, Inc.
    Inventors: Ruixiao LU, Michael CRAGER, Nan ZHANG, Tara MADDALA, Phillip FEBBO, Hugh Jeffrey LAWRENCE
  • Prostate cancer diagnosis and outcome prediction by expression analysis
    Publication number: 20060029971
    Abstract: Methods identifying prostate cancer, methods for prognosing and diagnosing prostate cancer, methods for identifying a compound that modulates prostate cancer development, methods for determining the efficacy of a prostate cancer therapy, and oligonucleotide microarrays containing probes for genes involved in prostate cancer development are described.
    Type: Application
    Filed: September 26, 2005
    Publication date: February 9, 2006
    Inventors: Todd Golub, Phillip Febbo, Kenneth Ross, William Sellers
  • Prostate cancer diagnosis and outcome prediction by expression analysis
    Publication number: 20060008838
    Abstract: Methods identifying prostate cancer, methods for prognosing and diagnosing prostate cancer, methods for identifying a compound that modulates prostate cancer development, methods for determining the efficacy of a prostate cancer therapy, and oligonucleotide microarrays containing probes for genes involved in prostate cancer development are described.
    Type: Application
    Filed: September 6, 2005
    Publication date: January 12, 2006
    Applicants: Whitehead Institute for Biomedical Research, Dana-Farber Cancer Institute, Inc.
    Inventors: Todd Golub, Phillip Febbo, Kenneth Ross, William Sellers